Nanjing Leads Biolabs Co (FRA:0DX) EV-to-OCF: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0DX Nanjing Leads Biolabs Co Ltd FRA:0DX
19 GF Score
Price €7.15
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Nanjing Leads Biolabs Co's Enterprise Value is €1,338.22 Mil. Nanjing Leads Biolabs Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil. Therefore, Nanjing Leads Biolabs Co's EV-to-OCF for today is .

The historical rank and industry rank for Nanjing Leads Biolabs Co's EV-to-OCF or its related term are showing as below:

FRA:0DX' s EV-to-OCF Range Over the Past 10 Years
Min: -85.71   Med: -55.8   Max: -42.4
Current: -71.84

During the past 3 years, the highest EV-to-OCF of Nanjing Leads Biolabs Co was -42.40. The lowest was -85.71. And the median was -55.80.

FRA:0DX's EV-to-OCF is ranked better than
95.53% of 1409 companies
in the Biotechnology industry
Industry Median: -3.63 vs FRA:0DX: -71.84

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-25), Nanjing Leads Biolabs Co's stock price is €7.15. Nanjing Leads Biolabs Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.147. Therefore, Nanjing Leads Biolabs Co's PE Ratio (TTM) for today is At Loss.

Nanjing Leads Biolabs Co  (FRA:0DX) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Nanjing Leads Biolabs Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.15/-0.147
=At Loss

Nanjing Leads Biolabs Co's share price for today is €7.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanjing Leads Biolabs Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.147.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Nanjing Leads Biolabs Co EV-to-OCF Related Terms

Nanjing Leads Biolabs Co EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co EV-to-OCF Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
EV-to-OCF
0.00 0.00 -49.52

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EV-to-OCF 0.00 0.00 0.00 0.00 -49.52

FRA:0DX vs VRTX, REGN, RVMD: EV-to-OCF Comparison

For the Biotechnology subindustry, Nanjing Leads Biolabs Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Leads Biolabs Co EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Nanjing Leads Biolabs Co's EV-to-OCF falls into.


FRA:0DX
19GF Score
Nanjing Leads Biolabs Co Ltd FRA:0DX
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co EV-to-OCF Calculation

Nanjing Leads Biolabs Co's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=1338.215/0
=

Nanjing Leads Biolabs Co's current Enterprise Value is €1,338.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanjing Leads Biolabs Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 09887:Hong Kong
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score

Get the complete analysis for FRA:0DX

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.15
Price